| Indication | For the treatment of pneumonia due to Pneumocystis carinii. |
| Pharmacodynamics | Pentamidine is an antiprotozoal agent. It is an aromatic diamidine, and is known to have activity against Pneumocystis carinii. The exact nature of its antiprotozoal action is unknown. in vitro studies with mammalian tissues and the protozoan Crithidia oncopelti indicate that the drug interferes with nuclear metabolism producing inhibition of the synthesis of DNA, RNA, phospholipids and proteins. Little is known about the drug's pharmacokinetics. The medication is also useful in Leishmaniasis and in prophylaxis against sleeping sickness caused by Trypanosoma brucei gambiense. Hydration before treatment lessens the incidence and severity of side effects, which include liver or kidney dysfunction, hypertension, hypotension, hypoglycemia, hypocalemia, leukopenia, thrombcytopenia, anemia, and allergic reaction. It is generally well-tolerated. |
| Mechanism of action | The mode of action of pentamidine is not fully understood. It is thought that the drug interferes with nuclear metabolism producing inhibition of the synthesis of DNA, RNA, phospholipids, and proteins. |
| Absorption | Absorbed poorly through the gastrointestinal tract and is usually administered parenterally. |
| Volume of distribution | Not Available |
| Protein binding | 69% |
| Metabolism | Hepatic. |
| Route of elimination | Not Available |
| Half life | 9.1-13.2 hours |
| Clearance | Not Available |
| Toxicity | Symptoms of overdose include pain, nausea, anorexia, hypotension, fever, rash, bad taste in mouth, confusion/hallucinations, dizziness, and diarrhea. |
Comments
Post a Comment